Metsera Inc MTSR
News
-
Pfizer Completes Acquisition of Metsera
-
Metsera Shares Fall Premarket as Novo Throws in Towel on Bidding War
-
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
-
Novo Nordisk Shares Rise After Withdrawal of Metsera Takeover Battle
-
Pfizer is losing its fight with Novo Nordisk to get back in the obesity-drug game
-
Pfizer Files Second Lawsuit Seeking to Block Novo Nordisk's Bid for Metsera
-
Novo Nordisk Seeks to Outmuscle Pfizer With Up to $9 Billion Bid for Metsera — 2nd Update
-
Novo Nordisk Seeks to Muscle Out Pfizer With Up to $9 Billion Bid for Metsera — Update
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 105.38M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 132
- Website
- https://www.metsera.com
Valuation
|
Metric
|
MTSR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 21.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MTSR
|
|---|---|
Quick Ratio | 4.13 |
Current Ratio | 4.25 |
Interest Coverage | −1,284.98 |
Quick Ratio
MTSR
Profitability
|
Metric
|
MTSR
|
|---|---|
Return on Assets (Normalized) | −43.57% |
Return on Equity (Normalized) | −136.48% |
Return on Invested Capital (Normalized) | −71.04% |
Return on Assets
MTSR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^GpdN$K | LOCK|%^L> | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@Pw@M?h | LOCK|YLy^m | $83B | |||
| Moderna Inc
MRNA
| LOCK|LdgJml | LOCK|H! | $80B | |||
| argenx SE ADR
ARGX
| LOCK|N?<XYYy | LOCK|@@? | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&N^VPr | LOCK|#wl | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&%QR>j | LOCK|T??& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|FQ&VmGMX | LOCK|%VLX | $28B | |||
| Incyte Corp
INCY
| LOCK|mdH#>Y | LOCK|Lt# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|F^RD?YD | LOCK|C? | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>$%ms# | LOCK|L%& | $14B |
United States